

DAY 2

Friday, March 6, 2020

E : English EL : Educational Lecture
LS : Luncheon Seminar **SS** : Sweets Seminar

		7:30	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:30	
Hall Building	Room1 4F Hall C			9:00~11:00 Symposium 1 Recent advances in genomics and genome-engineering in Hematology/Oncology Koichi Akashi, Seishi Ogawa P.3				12:35~13:00 Opening Ceremony	13:00~13:45 Special Planning 1 Minoko Takahashi, Shuichi Taniguchi	13:45~15:15 Symposium 2 Cord Blood Transplantation in Future Satoshi Takahashi, Shuichi Taniguchi P.4				18:30~ Mini Concert			
	Room2 7F Hall B7 (1)			9:00~10:00 Nursing Educational Lecture 1 Speaker: Yuka Ozasa Chair: Kazue Mori P.4	10:10~11:10 Oral Session for Nurse 1 Transplant Nursing Yumiko Shimizu Yuko Shimizu P.80		11:30~12:20 LS1 The importance of oral supportive care for hematopoietic stem cell transplantation recipients to fall our responsibility for it. Speaker: Yoshinobu Soga Chair: Maki Yokota (Chugai Pharmaceutical Co., Ltd.)		13:45~14:45 Nursing Educational Lecture 2 Speaker: Sanae Takanashi Chair: Megumi Fujisawa P.4	14:55~15:55 Bruch up on LTFU Nurse Sayaka Honma Hitomi Nishimoto P.5		16:10~17:00 SS1 High-dose chemotherapy in pediatric malignant solid tumor Speaker: Fuminori Iwasaki Chair: Masami Inoue, Tomoko Fukuchi (Sumitomo Dainippon Pharma Co., Ltd.)				Reception 19:30~21:30	
	Room3 7F Hall B7 (2)			9:00~10:30 Current Seminar 1 Koji Nagafuji, Takahiro Fukuda P.5		10:40~11:10 Current Seminar 2 Akihiro Shimosaka P.6	11:30~12:20 LS2 Daratumumab treatment for multiple myeloma Speaker: Kazutaka Sunami Chair: Tatsuo Ichinohe (Janssen Pharmaceutical K.K.)		13:30~14:40 Workshop 1 Yuichiro Nawa, Yoshikiyo Ito P.6	14:45~16:00 Workshop 2 Takehiko Mori, Yoshinobu Soga P.7							
	Room4 5F Hall B5		9:00~9:30 EL1 Speaker: Nobuhiro Tsukada Chair: Chieki Nakaseko P.7	9:35~10:05 EL2 Speaker: Tomohiro Morio Chair: Yoshiyuki Takahashi P.7	10:10~10:40 EL3 Speaker: Hiroki Yamaguchi Chair: Fumihiko Ishikawa P.8	10:45~11:15 EL4 Speaker: Gou Yamamoto Chair: Koji Idutsu P.8	11:30~12:20 LS3 Practice of relapsed/refractory acute lymphoblastic leukemia treatment in our hospital Speaker: Noriko Dokki Chair: Yosuke Minami (Pfizer Japan Inc.)		13:30~14:00 EL5 Speaker: Atsushi Kikuta Chair: Takahiro Fukuda P.8	14:05~14:35 EL6 Speaker: Atsushi Manabe Chair: Masami Inoue P.8	14:40~15:10 EL7 Speaker: Hiroshi Kimura Chair: Kimikazu Matsumoto P.9	15:15~15:45 EL8 Speaker: Takahiro Maeda Chair: Seishi Ogawa P.9	16:10~17:00 SS2 Pathophysiology and immune-targeted therapeutic approach of multiple myeloma in 2020 Speaker: Junya Kuroda Chair: Kazutaka Sunami (Bristol-Myers Squibb K.K.)				
	Room5 7F Hall D7		9:00~10:30 HCTC Workshop Shinichiro Mori, Yuka Nagai P.9				11:30~12:20 LS4 Brand new strategy for IFI management in evolving hematologic malignancy treatment approach Speaker: Toshihiro Miyamoto Chair: Takanori Teshima (MSD K.K.)		13:50~14:30 Oral Session for Nurse 2 LTFU/QOL Kazuyo Yoshikawa, Rei Yamaoka P.81	14:40~15:55 The allied organizations forum for promoting hematopoietic stem cell transplantation P.10		16:10~17:00 SS3 Multiple Myeloma 2020: Management of the Newly Diagnosed Transplant Eligible Patient Speaker: Jonathan L Kaufman Chair: Hideo Harigae (Janssen Pharmaceutical K.K.)					
	Room6 5F Hall D5		9:00~10:00 Oral Session 1 Transplant Source 1 Yasuyuki Arai P.21	10:10~11:10 Oral Session 2 Transplant Source 2 Yoshihiro Inamoto P.23			11:30~12:20 LS5 MSC for GVHD Speaker: Jun Kato, Motohiro Kato Chair: Koichi Miyamura (UCR Pharmaceuticals Co., Ltd.)		13:25~14:37 Oral Session 3 Transplant Source 3 Ayako Arai P.24	14:40~15:55 [Live Video] The forum of allied organizations promoting hematopoietic stem cell transplantation (HSCT)		16:10~17:00 SS4 Statistical analyses of stem cell transplantation data using EZR (Easy R) Speaker: Yoshinobu Kanda Chair: Satoshi Takahashi (Fuji Pharma Co., Ltd.)					
	Room7 1F Hall D1		9:00~10:00 Oral Session 4 Conditioning 1 Naomi Kawashima P.25	10:10~11:22 Oral Session 5 Conditioning 2 Shigeru Kusumoto P.26			11:30~12:20 LS6 New aspects of antifungal management after hematopoietic stem cell transplantation Speaker: Yuki Mori Chair: Makoto Murata (Sumitomo Dainippon Pharma Co., Ltd.)		13:30~14:42 Oral Session 6 Immune Reconstitution Shingo Kurahashi P.27	14:50~16:02 Oral Session 7 TDM/Drugs Takuro Nishikawa P.28		16:10~17:00 SS5 New treatment strategy for myelofibrosis Speaker: Shinsuke Takagi Chair: Masahiro Takeuchi (Novartis Pharma K.K.)					
	Room8 5F G502		9:00~9:48 Oral Session 8 GVHD/GVL 1 Hiroaki Shimizu P.29	10:10~10:58 Oral Session 9 GVHD/GVL 2 Kazutaka Ozeki P.30			11:30~12:20 LS7 Novel therapeutic strategy for relapsed/refractory AML Speaker: Takahiro Yamauchi Chair: Yasushi Miyazaki (DAICHI SANRYO COMPANY, LIMITED)		13:30~14:30 Oral Session 10 GVHD/GVL 3 Tomomi Toubai P.31	14:40~15:40 Oral Session 11 GVHD/GVL 4 Tatsunori Goto P.32		16:10~17:00 SS6 Key points for the introduction of the BCL2 inhibitor Venetoclax Speaker: Tomoki Ito Chair: Takanori Teshima, Ayako Mori (AbbVie GK)					
	Room9 5F G510		9:00~10:12 Oral Session 12 Early Complication (TMA/SOS) Takahiko Nakane P.33		10:20~11:08 Oral Session 13 Early Complication (Engraftment Failure) Satoshi Nishiwaki P.34		11:30~12:20 LS8 Factors predicting outcome after allogeneic HSCT for myelofibrosis Speaker: Shingo Yano (NOCHIDA PHARMACEUTICAL CO., LTD.)		13:30~14:42 Oral Session 14 Early Complication (Pretransplant Evaluation/ Others) Hisayuki Yokoyama P.35	14:50~16:02 Oral Session 15 Early Complication (Heart/Lungs/Central Nervous System) Kentaro Fukushima P.36		16:10~17:00 SS7 Overcoming challenges of refractory AML: Current situation and the future prospect including FLT3 inhibitors Speaker: Naoyuki Uchida Chair: Kouichi Akashi (Astellas Pharma Inc.)					
	Room10 4F G402		9:00~10:00 Oral Session 16 Viral Infection 1 Takanobu Morishita P.37	10:10~11:10 Oral Session 17 Viral Infection 2 Akihiro Yokoyama P.38			11:30~12:20 LS9 Management of cytomegalovirus infection in the Bcr/a era. -Choosing wisely- Speaker: Yoshinobu Kanda Chair: Takahiko Mori (Mitsubishi Tanabe Pharma Corporation)		13:30~14:30 Oral Session 18 Immunotherapy/Cell Therapy 1 Kazuhiko Ikeda P.39	14:40~15:40 Oral Session 19 Immunotherapy/Cell Therapy 2 Shinichi Kako P.40		16:10~17:00 SS8 Intravenous Access in Hematopoietic Stem Cell Transplantation -Usefulness of PICC- Speaker: Yasuyuki Arai Chair: Yoshinobu Maeda (Nippon Becton Dickinson Company Ltd.)					
	Room11 4F G409		9:00~10:00 Oral Session 20 LTFU/QOL Yasuyuki Inoue P.41	10:10~11:10 Oral Session 21 Immunization Satoshi Iyama P.42			11:30~12:20 LS10 Update on treatment and diagnosis of GVHD Speaker: Yoshinobu Inamoto Chair: Yoshinobu Maeda (Novartis Pharma K.K.)		13:30~14:30 Oral Session 22 Nutrition Management 1 Shigeo Fuji P.43	14:40~15:28 Oral Session 23 Nutrition Management 2 Sachiko Seo P.44		16:10~17:00 SS9 Current status and future perspective of conditioning regimen for allogeneic stem cell transplantation Speaker: Hisashi Yamamoto Chair: Masashi Sawa (Otsuka Pharmaceutical Co., Ltd.)					
	Room12 6F G602		9:00~10:00 Oral Session 24 Rehabilitation 1 Eisei Kondo P.45	10:10~11:10 Oral Session 25 Rehabilitation 2 Hiroya Tamaki P.46			11:30~12:20 LS11 Optimizing stem cell mobilization in the era of plerixafor Speaker: Nobuhiro Tsukada Chair: Masahiro Kizaki (Sanofi K.K.)		13:30~14:42 Oral Session 26 Management/Care/Team Medical-care Taku Kikuchi P.47	14:50~15:50 Oral Session 27 Histocompatibility Antigen Ilseung Choi P.48		16:10~17:00 SS10 Management and follow-up after hematopoietic stem cell transplantation Speaker: Ryoji Kobayashi Chair: Sakiko Kondo (Novartis Pharma K.K.)					
Hall E	Poster B2F	8:30~10:00 Poster mounting		10:00~17:15 Poster viewing													17:15~18:00 Poster Presentation
	Exhibition B2F	9:00~18:00 Exhibition															

Poster Presentation

- P-001~P-009 Stem Cell Mobilization and Collection
- P-011~P-015 Transplant Source
- P-017~P-023 Conditioning
- P-025~P-047 Transplant Immunity
- P-049~P-053 Immunotherapy/Cell Therapy
- P-055 Child-specific Transplant Disease
- P-057~P-099 Transplant Outcomes
- P-101~P-117 Malignant Lymphoma/ATL
- P-119~P-133 Minimal Residual Disease and Recurrence
- P-135~P-145 Early Complication
- P-147~P-183 Late Complication
- P-185~P-193 Bacterial Infection
- P-195~P-213 Viral Infection
- P-215~P-227 Fungal Infection/Other Infection
- P-229~P-231 LTFU/QOL
- P-233~P-235 Marrow Donor Program/Cord Blood Bank/Donors
- P-237 Hematopoietic Cell Transplant Coordinator and Coordinate
- P-239~P-249 Management/Care/Team Medical-care
- P-251~P-267 Rehabilitation
- P-269~P-275 TDM/Drugs

Nursing Poster Presentation

- NurseP1-01~P1-12 Care
- NurseP1-13~P1-14 Infection control
- NurseP1-15~P1-22 Follow-up
- NurseP1-23~P1-27 Decision support
- NurseP1-28 Team approach
- NurseP1-29~P1-32 Nursing Management, Education